Lupus & antiphospholipid syndrome
Risk of end-stage renal disease in patients with early-onset lupus nephritis: A population-based cohort study
Main finding · Progression to ESRDResult — go to the resultHazard ratio 1.10 95 % CI 0.57–2.11Authors' conclusion
The risk of ESRD was comparable between patients with EOLN and DOLN. However, among patients on aggressive immunosuppressive therapy, compared with EOLN, DOLN was associated with a higher risk of progression to ESRD.
Study context
- Population
- Incident systemic lupus erythematosus (SLE) patients who developed LN, nationwide Korean claims databases, 2008–2018
- Participants
- 3,779 patients
- Exposure
- Early-onset LN vs delayed-onset LN
- Early-onset lupus nephritis (EOLN)n = 2,281
- Delayed-onset LN (DOLN)n = 1,489reference
- Outcome
- Progression to end-stage renal disease (ESRD)
Methodological detailspopulation-based, nationwide Korean claims databases, Cox proportional hazards with death as competing risk
- Population-based
- Nationwide Korean claims databases
- Cox proportional hazards with death as competing risk
Main finding
As reported in the abstract
Hazard ratio
1.10
95 % CI 0.57–2.11
Events by group
EOLNvs DOLN
HR 1.10 (95 % CI 0.57–2.11)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95 % CI) | |
|---|---|---|
| ESRD in patients on aggressive immunosuppressive therapy (subgroup)670 EOLN and 179 DOLN | 2.6 (1.11–6.10) | |
| 0.10.31310Hazard ratio (log scale) |
Original publication
Risk of end-stage renal disease in patients with early-onset lupus nephritis: A population-based cohort study. Semin Arthritis Rheum. Published 4 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →